Stoke Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 6, 2024

STOK$26.54+1.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets

	March 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$178,581	$191,442
Marketable securities	—	9,952
Prepaid expenses	10,722	11,320
Other current assets	3,559	2,561
Deferred financing costs	402	—
Interest receivable	11	64
Total current assets	$193,275	$215,339
Restricted cash	569	569
Operating lease right-of-use assets	6,060	6,611
Property and equipment, net	5,278	5,823
Total Assets	$205,182	$228,342
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,102	$1,695
Accrued and other current liabilities	12,570	13,815
Deferred revenue - current portion	20,918	15,309
Total current liabilities	$35,590	$30,819
Deferred revenue - net of current portion	25,042	33,074
Other long term liabilities	4,208	4,884
Total long term liabilities	29,250	37,958
Total liabilities	$64,840	$68,777
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 46,498,077 and 45,918,233 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	568,560	561,433
Accumulated other comprehensive loss	—	(24)
Accumulated deficit	(428,223)	(401,849)
Total stockholders’ equity	$140,342	$159,565
Total liabilities and stockholders’ equity	$205,182	$228,342

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.